サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392822

ペプチド系抗生物質の世界市場レポート 2024年

Peptide Antibiotics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペプチド系抗生物質の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ペプチド系抗生物質の市場規模は近年急速に拡大しています。2023年の47億9,000万米ドルから2024年には53億1,000万米ドルへとCAGR 11.0％で拡大します。過去の期間に観察された成長は、ペプチド系抗生物質の発見と開発、抗生物質耐性の増加、感染症の発生率の上昇、ペプチド合成技術の進歩、製薬業界の全体的な成長などの要因に起因しています。

ペプチド系抗生物質市場のもう一つの重要な促進要因は、慢性疾患の発生率の上昇です。慢性疾患は、1年以上持続し、継続的な治療が必要な疾患で、タバコの増加、栄養不良、座りっぱなしのライフスタイルなどの要因で増加しています。ペプチド系抗生物質は、的を絞った薬剤投与を行うことで、慢性疾患の治療に重要な役割を果たしています。全米高齢化評議会（National Council on Aging, Inc.）の報告によると、高齢者人口の85％以上が少なくとも1つの慢性疾患と闘っており、米国の年間医療支出は3兆8,000億米ドルに達しています。したがって、慢性疾患の有病率の上昇がペプチド系抗生物質市場の成長を促進する重要な要因となっています。

2023年のペプチド系抗生物質市場で最大の地域は北米でした。

目次

第1章 エグゼクティブサマリー

第2章 ペプチド系抗生物質市場の特徴

第3章 ペプチド系抗生物質市場の動向と戦略

第4章 ペプチド系抗生物質市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界のペプチド系抗生物質市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033F

第6章 ペプチド系抗生物質市場セグメンテーション

  • 世界のペプチド系抗生物質市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • リボソーム合成ペプチド系抗生物質
  • 非リボソーム合成ペプチド系抗生物質
  • 世界のペプチド系抗生物質市場、医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • ダプトマイシン
  • ダルババンシン
  • テラヴァンシン
  • その他
  • 世界のペプチド系抗生物質市場、疾患別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 皮膚感染症
  • HABP/VABP
  • 血流感染症
  • その他
  • 世界のペプチド系抗生物質市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第7章 ペプチド系抗生物質市場の地域別・国別分析

  • 世界のペプチド系抗生物質市場、地域別、実績および予測、2018-2023、2023-2028F、2033F
  • 世界のペプチド系抗生物質市場、国別、実績および予測、2018-2023、2023-2028F、2033F

第8章 アジア太平洋のペプチド系抗生物質市場

  • 概要
  • 地域情報、COVID-19症の影響、市場情報、背景情報、政府の取り組み、規制、規制機関、主要団体、課税額、法人税構造、投資、主要企業
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第9章 中国のペプチド系抗生物質市場

第10章 インドのペプチド系抗生物質市場

第11章 日本のペプチド系抗生物質市場

第12章 オーストラリアのペプチド系抗生物質市場

第13章 インドネシアのペプチド系抗生物質市場

第14章 韓国のペプチド系抗生物質市場

第15章 西欧のペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第16章 英国のペプチド系抗生物質市場

第17章 ドイツのペプチド系抗生物質市場

第18章 フランスのペプチド系抗生物質市場

第19章 イタリアのペプチド系抗生物質市場

第20章 スペインのペプチド系抗生物質市場

第21章 東欧のペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第22章 ロシアのペプチド系抗生物質市場

第23章 北米のペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第24章 米国のペプチド系抗生物質市場

第25章 カナダのペプチド系抗生物質市場

第26章 南米のペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第27章 ブラジルのペプチド系抗生物質市場

第28章 中東のペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第29章 アフリカのペプチド系抗生物質市場

  • 概要
  • タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F
  • 流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028F、2033F

第30章 ペプチド系抗生物質市場の競合情勢と企業プロファイル

  • ペプチド系抗生物質市場の競合情勢
  • ペプチド系抗生物質市場の企業プロファイル
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer Inc.
    • Theravance Biopharma Inc

第31章 世界のペプチド系抗生物質市場の競合ベンチマーキング

第32章 世界のペプチド系抗生物質市場の競合ダッシュボード

第33章 ペプチド系抗生物質市場における主要な合併と買収

第34章 ペプチド系抗生物質市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10510

“Peptide Antibiotics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide antibiotics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The peptide antibiotics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Ribosomal Synthesized Peptide Antibiotics; Non-ribosomal Synthesized Peptide Antibiotics
  • 2) By Drugs: Daptomycin; Dalbavancin; Telavancin; Other Drugs
  • 3) By Disease Outlook: Skin Infection; HABP/VABP; Blood Stream Infection; Other Diseases
  • 4) By Distribution Channel: Hospitals; Homecare; Specialty Clinics; Other Distribution Channels
  • Companies Mentioned: Eli Lilly and Company; GlaxoSmithKline plc; Novartis AG; Pfizer Inc.; Theravance Biopharma Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Peptide antibiotics are a type of antibiotics composed of peptides, and their antibacterial activity is based on the physical rupture of cell membranes. These antibiotics are designed to permeate bacterial membranes, accumulate within bacteria, and subsequently interfere with bacterial functioning.

The main types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics can either destroy or modify the drug, change the drug target, decrease or raise drug uptake, or substitute a different metabolic step as the medication's target. These antibiotics are antimicrobial peptides generated by ribosomes and produced by a wide range of species, from bacteria to plants and animals. Some examples of drugs under the category of peptide antibiotics include daptomycin, dalbavancin, telavancin, and other drugs used to treat various diseases such as skin infections, hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), bloodstream infections, and other conditions. Peptide antibiotics are utilized and distributed through channels like hospitals, homecare, specialty clinics, and other distribution channels.

The peptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide antibiotics market size has grown rapidly in recent years. It will grow from $4. 79 billion in 2023 to $5. 31 billion in 2024 at a compound annual growth rate (CAGR) of 11. 0%. The growth observed in the historic period can be attributed to factors such as the discovery and development of peptide antibiotics, an increase in antibiotic resistance, a rise in the incidence of infectious diseases, advancements in peptide synthesis technologies, and the overall growth of the pharmaceutical industry.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $7. 78 billion in 2028 at a compound annual growth rate (CAGR) of 10. 0%. The anticipated growth in the forecast period can be attributed to an emphasis on the development of novel antibiotics, the increasing global incidence of antibiotic-resistant infections, the expansion of research and development in antimicrobial peptides, and regulatory support for new antibiotic approvals. Major trends expected in the forecast period include the exploration of natural sources for antimicrobial peptides, the application of peptide antibiotics in animal health, a focus on peptide engineering for enhanced efficacy, the development of combination peptide antibiotics, and the integration of artificial intelligence and machine learning in peptide antibiotic discovery.

The growth of the peptide antibiotics market is anticipated to be propelled by the increasing prevalence of various infectious diseases. These diseases, caused by microorganisms like bacteria, fungi, and parasites, have witnessed a surge due to factors such as rapid urbanization, climate change, and an elevated risk of disease emergence. The demand for peptide antibiotics has risen in response to these trends, as they exert antibacterial activity by physically rupturing cell membranes. Notably, data from the Australian Institute of Health and Welfare revealed a substantial increase in notifiable infectious disease cases in Australia, rising from 2. 89 million in 2020 to 7. 02 million in 2021. This surge underscores the driving force of the growing incidence of infectious diseases in advancing the peptide antibiotics market.

Another significant driver for the peptide antibiotics market is the escalating incidence of chronic diseases. Chronic conditions, enduring for a year or more and requiring ongoing medical attention, have seen an uptick due to factors such as increased tobacco use, poor nutrition, and sedentary lifestyles. Peptide antibiotics play a crucial role in treating chronic diseases by delivering targeted drug administration. A report by the National Council on Aging, Inc., highlighted that over 85% of the elderly population grapples with at least one chronic illness, contributing to the annual healthcare spending in the US reaching $3. 8 trillion. Hence, the rising prevalence of chronic conditions is a key factor propelling the growth of the peptide antibiotics market.

A prominent trend in the peptide antibiotics market is the increasing adoption of strategic partnerships among major companies. This collaborative approach allows companies to expand their market reach and leverage each other's resources effectively. For instance, Berkeley Lights, a US-based digital cell biology company, forged a strategic partnership with Aanika Biosciences in January 2022. Through this collaboration, Aanika Biosciences aims to utilize Berkeley Lights' high-throughput, functional screening service to rapidly identify and refine functional antimicrobial peptides (AMPs) targeting harmful bacteria, particularly those responsible for foodborne disease outbreaks. The partnership also involves the utilization of the Beacon Optofluidic Platform to identify peptides harmful to bacteria, leading to the development of a novel antibacterial tag. This tag will be integrated into Aanika Biosciences' bacterial spore-based barcoding technology to enhance food supply chain security.

Major players in the peptide antibiotics market are also making strategic moves by introducing generic versions, providing a cost-effective alternative for patients. Generic versions, which are off-patent alternatives to brand-name peptide-based antibiotics, offer affordability without compromising efficacy. In July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its portfolio by launching a generic version of Daptomycin for Injection. This peptide antibiotic is a cyclic lipopeptide synthesized by nonribosomal machinery and is prescribed for treating complicated skin and skin structure infections (cSSSI) in both adult and pediatric patients aged 1 to 17 years.

Major companies operating in the in the peptide antibiotics market report are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Theravance Biopharma Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, AuroMedics Pharma LLC, EnBiotix Inc., Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, AdvaCare Pharma, Allecra Therapeutics GmbH, AmpliPhi Biosciences Corporation, Antabio, Arsanis Inc., Basilea Pharmaceutica Ltd., BioVersys AG, Curis Inc.

North America was the largest region in the peptide antibiotics market in 2023. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the peptide antibiotics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Peptide Antibiotics Market Characteristics

3. Peptide Antibiotics Market Trends And Strategies

4. Peptide Antibiotics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Peptide Antibiotics Market Size and Growth

  • 5.1. Global Peptide Antibiotics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Peptide Antibiotics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Peptide Antibiotics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Peptide Antibiotics Market Segmentation

  • 6.1. Global Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ribosomal Synthesized Peptide Antibiotics
  • Non-ribosomal Synthesized Peptide Antibiotics
  • 6.2. Global Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Daptomycin
  • Dalbavancin
  • Telavancin
  • Other Drugs
  • 6.3. Global Peptide Antibiotics Market, Segmentation By Disease Outlook, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Skin Infection
  • HABP/VABP
  • Blood Stream Infection
  • Other Diseases
  • 6. 4. Global Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other Distribution Channels

7. Peptide Antibiotics Market Regional And Country Analysis

  • 7.1. Global Peptide Antibiotics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Peptide Antibiotics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Peptide Antibiotics Market

  • 8.1. Asia-Pacific Peptide Antibiotics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Peptide Antibiotics Market

  • 9.1. China Peptide Antibiotics Market Overview
  • 9.2. China Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Peptide Antibiotics Market

  • 10.1. India Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Peptide Antibiotics Market

  • 11.1. Japan Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Peptide Antibiotics Market

  • 12.1. Australia Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Peptide Antibiotics Market

  • 13.1. Indonesia Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Peptide Antibiotics Market

  • 14.1. South Korea Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Peptide Antibiotics Market

  • 15.1. Western Europe Peptide Antibiotics Market Overview
  • 15.2. Western Europe Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Peptide Antibiotics Market

  • 16.1. UK Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Peptide Antibiotics Market

  • 17.1. Germany Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Peptide Antibiotics Market

  • 18. 5. France Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Peptide Antibiotics Market

  • 19. 9. Italy Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Peptide Antibiotics Market

  • 20.13. Spain Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Peptide Antibiotics Market

  • 21.1. Eastern Europe Peptide Antibiotics Market Overview
  • 21.2. Eastern Europe Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Peptide Antibiotics Market

  • 22.1. Russia Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Peptide Antibiotics Market

  • 23.1. North America Peptide Antibiotics Market Overview
  • 23.2. North America Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Peptide Antibiotics Market

  • 24.1. USA Peptide Antibiotics Market Overview
  • 24.2. USA Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Peptide Antibiotics Market

  • 25.1. Canada Peptide Antibiotics Market Overview
  • 25.2. Canada Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Peptide Antibiotics Market

  • 26.1. South America Peptide Antibiotics Market Overview
  • 26.2. South America Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Peptide Antibiotics Market

  • 27.1. Brazil Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Peptide Antibiotics Market

  • 28.1. Middle East Peptide Antibiotics Market Overview
  • 28.2. Middle East Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Peptide Antibiotics Market

  • 29.1. Africa Peptide Antibiotics Market Overview
  • 29.2. Africa Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Peptide Antibiotics Market Competitive Landscape And Company Profiles

  • 30.1. Peptide Antibiotics Market Competitive Landscape
  • 30.2. Peptide Antibiotics Market Company Profiles
    • 30.2.1. Eli Lilly and Company
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. GlaxoSmithKline plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Pfizer Inc.
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Theravance Biopharma Inc
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Peptide Antibiotics Market Competitive Benchmarking

32. Global Peptide Antibiotics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Peptide Antibiotics Market

34. Peptide Antibiotics Market Future Outlook and Potential Analysis

  • 34.1 Peptide Antibiotics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Peptide Antibiotics Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Peptide Antibiotics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer